Weller, Johannes and Zeyen, Thomas and Schaefer, Niklas and Schaub, Christina and Potthoff, Anna-Laura and Steinbach, Joachim P. and Hau, Peter and Seidel, Clemens and Goldbrunner, Roland and Tabatabai, Ghazaleh and Vatter, Hartmut and Tzaridis, Theophilos and Schneider, Matthias and Herrlinger, Ulrich (2023) The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial. JOURNAL OF NEURO-ONCOLOGY, 164 (3). pp. 749-755. ISSN 0167-594X, 1573-7373
Full text not available from this repository. (Request a copy)Abstract
PurposeThe AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate these findings in an independent trial cohort.MethodsWe evaluate the treatment benefit of bevacizumab according to gene expression subtypes of pretreatment tumor samples (n = 123) in the GLARIUS trial (NCT00967330) for MGMT unmethylated glioblastoma patients with Kaplan-Meier analyses, log-rank tests and Cox regression models.ResultsEmploying the Phillips classifier, bevacizumab conferred a significant PFS advantage in patients with proneural IDH wild-type tumors (10.4 vs. 6.0 months, p = 0.002), but no OS advantage (16.4 vs. 17.4 months, p = 0.6). Multivariable analysis adjusting for prognostic covariates confirmed the absence of a significant OS advantage from bevacizumab (hazard ratio, 1.05, 95% CI, 0.42 to 2.64; p = 0.14). Further, there was no interaction between the proneural subtype and treatment arm (p = 0.15). These results were confirmed in analyses of tumor subgroups according to the Verhaak classifier.ConclusionIn contrast to AVAglio, glioblastoma gene expression subgroups were not associated with a differential OS benefit from first-line bevacizumab in the GLARIUS trial.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TEMOZOLOMIDE; RADIOTHERAPY; Glioblastoma; Newly diagnosed glioblastoma; Bevacizumab; Gene expression |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Mar 2024 14:51 |
| Last Modified: | 14 Mar 2024 14:51 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60132 |
Actions (login required)
 |
View Item |
